
## Su-Fang Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1775918/publications.pdf Version: 2024-02-01



SU-FANCLIN

#	Article	IF	CITATIONS
1	c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation. Theranostics, 2021, 11, 5232-5247.	4.6	48
2	ldentification of Prognostic Biomarkers Originating From the Tumor Stroma of Betel Quid-Associated Oral Cancer Tissues. Frontiers in Oncology, 2021, 11, 769665.	1.3	5
3	Index of Cancer-Associated Fibroblasts Is Superior to the Epithelial–Mesenchymal Transition Score in Prognosis Prediction. Cancers, 2020, 12, 1718.	1.7	18
4	Discoidin Domain Receptor-1 (DDR1) is Involved in Angiolymphatic Invasion in Oral Cancer. Cancers, 2020, 12, 841.	1.7	16
5	MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 281.	3.5	61
6	Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis. Cancers, 2019, 11, 1795.	1.7	21
7	Recapitulation of inflammatory and immune-evasive subtypes of oral cancer cells in immunodeficient mice Journal of Clinical Oncology, 2019, 37, e14199-e14199.	0.8	0
8	The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1. Journal of Virology, 2017, 91, .	1.5	16
9	Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes. Journal of Virology, 2017, 91, .	1.5	6
10	Epstein-Barr virus BRLF1 induces genomic instability and progressive malignancy in nasopharyngeal carcinoma cells. Oncotarget, 2017, 8, 78948-78964.	0.8	18
11	The Ubiquitin Ligase Itch and Ubiquitination Regulate BFRF1-Mediated Nuclear Envelope Modification for Epstein-Barr Virus Maturation. Journal of Virology, 2016, 90, 8994-9007.	1.5	39
12	Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes. Antiviral Research, 2016, 132, 99-110.	1.9	42
13	EBV reactivation as a target of luteolin to repress NPC tumorigenesis. Oncotarget, 2016, 7, 18999-19017.	0.8	31
14	Nuclear Translocation and Regulation of Intranuclear Distribution of Cytoplasmic Poly(A)-Binding Protein Are Distinct Processes Mediated by Two Epstein Barr Virus Proteins. PLoS ONE, 2014, 9, e92593.	1.1	16
15	Epstein-Barr Virus BALF3 Has Nuclease Activity and Mediates Mature Virion Production during the Lytic Cycle. Journal of Virology, 2014, 88, 4962-4975.	1.5	25
16	Inhibition of epsteinâ€barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane. Molecular Carcinogenesis, 2013, 52, 946-958.	1.3	33
17	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery, 2013, 3, 636-647.	7.7	614
18	Reactive Oxygen Species Mediate Epstein-Barr Virus Reactivation by N-Methyl-N'-Nitro-N-Nitrosoguanidine. PLoS ONE, 2013, 8, e84919.	1.1	38

Su-Fang Lin

#	Article	IF	CITATIONS
19	Epstein–Barr virus Rta-mediated transactivation of p21 and 14-3-3ïƒ arrests cells at the G1/S transition by reducing cyclin E/CDK2 activity. Journal of General Virology, 2012, 93, 139-149.	1.3	24
20	Ser-634 and Ser-636 of Kaposi's Sarcoma-Associated Herpesvirus RTA are Involved in Transactivation and are Potential Cdk9 Phosphorylation Sites. Frontiers in Microbiology, 2012, 3, 60.	1.5	14
21	Suppressive Regulation of KSHV RTA with O-GlcNAcylation. Journal of Biomedical Science, 2012, 19, 12.	2.6	22
22	Epstein-Barr Virus BGLF4 Kinase Retards Cellular S-Phase Progression and Induces Chromosomal Abnormality. PLoS ONE, 2012, 7, e39217.	1.1	51
23	Epstein–Barr Virus (EBV) Rta-Mediated EBV and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivations in 293 Cells. PLoS ONE, 2011, 6, e17809.	1.1	16
24	Histone Demethylase JMJD2A Regulates Kaposi's Sarcoma-Associated Herpesvirus Replication and Is Targeted by a Viral Transcriptional Factor. Journal of Virology, 2011, 85, 3283-3293.	1.5	52
25	Gene Expression and Transcription Factor Profiling Reveal Inhibition of Transcription Factor cAMP-response Element-binding Protein by Î <sup>3</sup> -Herpesvirus Replication and Transcription Activator. Journal of Biological Chemistry, 2010, 285, 25139-25153.	1.6	9
26	The M Type K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus Regulates MicroRNA Expression via Its SH2-Binding Motif To Induce Cell Migration and Invasion. Journal of Virology, 2009, 83, 622-632.	1.5	72
27	The Epstein-Barr virus replication and transcription activator, Rta/BRLF1, induces cellular senescence in epithelial cells. Cell Cycle, 2009, 8, 58-65.	1.3	34
28	Epstein-Barr Virus BGLF4 Kinase Induces Disassembly of the Nuclear Lamina To Facilitate Virion Production. Journal of Virology, 2008, 82, 11913-11926.	1.5	104
29	Cell Cycle Regulation by Kaposi's Sarcoma-Associated Herpesvirus K-bZIP: Direct Interaction with Cyclin-CDK2 and Induction of G 1 Growth Arrest. Journal of Virology, 2003, 77, 9652-9661.	1.5	58
30	Kaposi's Sarcoma-Associated Herpesvirus K-bZIP Is a Coregulator of K-Rta: Physical Association and Promoter-Dependent Transcriptional Repression. Journal of Virology, 2003, 77, 1441-1451.	1.5	99
31	K-bZIP of Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 (KSHV/HHV-8) Binds KSHV/HHV-8 Rta and Represses Rta-Mediated Transactivation. Journal of Virology, 2003, 77, 3809-3815.	1.5	61
32	Identification of the bZIP and Rta Homologues in the Genome of Rhesus Monkey Rhadinovirus. Virology, 2002, 298, 181-188.	1.1	20
33	Marek's Disease Virus (MDV) Encodes an Interleukin-8 Homolog (vIL-8): Characterization of the vIL-8 Protein and a vIL-8 Deletion Mutant MDV. Journal of Virology, 2001, 75, 5159-5173.	1.5	152
34	The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19, 5548-5557.	2.6	973
35	Dihydrofolate Reductase from Kaposi's Sarcoma-Associated Herpesvirus. Virology, 2000, 268, 201-217.	1.1	15
36	Kaposi's Sarcoma-Associated Herpesvirus Encodes a bZIP Protein with Homology to BZLF1 of Epstein-Barr Virus. Journal of Virology, 1999, 73, 1909-1917.	1.5	115

Su-Fang Lin

#	Article	IF	CITATIONS
37	Kinetics of Kaposi's Sarcoma-Associated Herpesvirus Gene Expression. Journal of Virology, 1999, 73, 2232-2242.	1.5	356
38	Distinct Regions of EBV DNase Are Required for Nuclease and DNA Binding Activities. Virology, 1998, 242, 6-13.	1.1	7
39	High Prevalence of Antibodies to Human Herpesvirus 8 in Relatives of Patients with Classic Kaposi's Sarcoma from Sardinia. Journal of Infectious Diseases, 1998, 177, 1715-1718.	1.9	93
40	A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10866-10871.	3.3	546
41	SEROLOGIC ASSOCIATION OF HUMAN HERPESVIRUS EIGHT WITH POSTTRANSPLANT KAPOSI'S SARCOMA IN SAUDI ARABIA1. Transplantation, 1998, 65, 583-585.	0.5	76
42	The transcriptional activator Sp1, a novel autoantigen. Arthritis and Rheumatism, 1997, 40, 1085-1095.	6.7	7
43	Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. Journal of Virology, 1997, 71, 3069-3076.	1.5	82
44	Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11883-11888.	3.3	189
45	Characterization of Epstein-Barr Virus DNase and Its Interaction with the Major DNA Binding Protein. Virology, 1995, 208, 712-722.	1.1	20
46	Functional Analysis of the Amino Terminus of Epstein-Barr Virus Deoxyribonuclease. Virology, 1994, 199, 223-227.	1.1	13
47	Autoantigenic proteins that bind recombinogenic sequences in Epstein-Barr virus and cellular DNA	0.0	17

477	Autoantigenic proteins that ond recombinogenic sequences in cpstein-bait virus and cenular DNA	0.0	177
47	Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8646-8650.	3.3	1/
	Proceedings of the National Academy of Sciences of the difficult States of America, 1994, 91, 0040-0090.		